Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 9132052, 5 pages
http://dx.doi.org/10.1155/2016/9132052
Research Article

The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

1Diabetes Unit, Niguarda Cà Granda Hospital, 20162 Milan, Italy
2Diabetes Unit, Cantù Hospital, 20081 Abbiategrasso, Italy

Received 24 May 2016; Revised 14 August 2016; Accepted 20 September 2016

Academic Editor: Vittorio Unfer

Copyright © 2016 Basilio Pintaudi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Pak, L. C. Huang, K. J. Lilley, and J. Larner, “In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues,” The Journal of Biological Chemistry, vol. 267, no. 24, pp. 16904–16910, 1992. View at Google Scholar · View at Scopus
  2. H. K. Ortmeyer, L. C. Huang, L. Zhang, B. C. Hansen, and J. Larner, “Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys,” Endocrinology, vol. 132, no. 2, pp. 646–651, 1993. View at Google Scholar · View at Scopus
  3. H. K. Ortmeyer, “Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys,” Obesity Research, vol. 4, no. 6, pp. 569–575, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. M. L. Croze and C. O. Soulage, “Potential role and therapeutic interests of myo-inositol in metabolic diseases,” Biochimie, vol. 95, no. 10, pp. 1811–1827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Larner, “D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance,” International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Unfer and G. Porcaro, “Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome,” Expert Review of Clinical Pharmacology, vol. 7, no. 5, pp. 623–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Dinicola, T. T. Y. Chiu, V. Unfer, G. Carlomagno, and M. Bizzarri, “The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome,” Journal of Clinical Pharmacology, vol. 54, pp. 1079–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, “Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials,” Gynecological Endocrinology, vol. 28, no. 7, pp. 509–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Giordano, F. Corrado, A. Santamaria et al., “Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study,” Menopause, vol. 18, no. 1, pp. 102–104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Santamaria, D. Giordano, F. Corrado et al., “One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome,” Climacteric, vol. 15, no. 5, pp. 490–495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. J. Crawford, C. A. Crowther, J. Alsweiler, and J. Brown, “Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes,” The Cochrane Database of Systematic Reviews, no. 12, Article ID CD011507, 2015. View at Publisher · View at Google Scholar
  12. A. Santamaria, A. Di Benedetto, E. Petrella et al., “Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 23, pp. 1–4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. D'Anna, A. Di Benedetto, A. Scilipoti et al., “Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial,” Obstetrics & Gynecology, vol. 126, no. 2, pp. 310–315, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. R. D'Anna, A. Scilipoti, D. Giordano et al., “Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study,” Diabetes Care, vol. 36, no. 4, pp. 854–857, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Corrado, R. D'Anna, G. di Vieste et al., “The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes,” Diabetic Medicine, vol. 28, no. 8, pp. 972–975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Lubin, R. Shojai, P. Darmon, and E. Cosson, “A pilot study of gestational diabetes mellitus not controlled by diet alone: first-line medical treatment with myoinositol may limit the need for insulin,” Diabetes & Metabolism, vol. 42, no. 3, pp. 192–195, 2016. View at Publisher · View at Google Scholar
  17. V. T. Samuel and G. I. Shulman, “Mechanisms for insulin resistance: common threads and missing links,” Cell, vol. 148, no. 5, pp. 852–871, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. I. W. Campbell and H. C. S. Howlett, “Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis,” Diabetes/Metabolism Reviews, vol. 11, supplement 1, pp. S57–S62, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Johansen, “Efficacy of metformin in the treatment of NIDDM: meta-analysis,” Diabetes Care, vol. 22, no. 1, pp. 33–37, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group,” JAMA, vol. 281, no. 21, pp. 2005–2012, 1999. View at Google Scholar
  21. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Publisher · View at Google Scholar
  22. J. Perk, G. DeBacker, H. Gohlke et al., “European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts),” European Heart Journal, vol. 33, no. 13, pp. 1635–1701, 2012. View at Publisher · View at Google Scholar
  23. “Standards of medical care in diabetes-2016,” Diabetes Care, vol. 39, supplement 1, 2016.
  24. T.-H. Sun, D. B. Heimark, T. Nguygen, J. L. Nadler, and J. Larner, “Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls,” Biochemical and Biophysical Research Communications, vol. 293, no. 3, pp. 1092–1098, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. International Diabetes Federation, 2015, http://www.diabetesatlas.org.
  26. M. Shichiri, H. Kishikawa, Y. Ohkubo, and N. Wake, “Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients,” Diabetes Care, vol. 23, supplement 2, pp. B21–B29, 2000. View at Google Scholar · View at Scopus
  27. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, “Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis,” Diabetes Research and Clinical Practice, vol. 79, no. 2, pp. 196–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S.-C. Liu, Y.-K. Tu, M.-N. Chien, and K.-L. Chien, “Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis,” Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 810–820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Sudchada, S. Saokaew, S. Sridetch, S. Incampa, S. Jaiyen, and W. Khaithong, “Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis,” Diabetes Research and Clinical Practice, vol. 98, no. 1, pp. 151–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Agostini, F. Rossi, and R. Pajalich, “Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study,” European Review for Medical and Pharmacological Sciences, vol. 10, no. 5, pp. 247–250, 2006. View at Google Scholar · View at Scopus